Trial reportAntimicrobial agents and chemotherapy2023
No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
Trial report in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Drug-Drug Interaction of Ainuovirine with Fluconazole in Healthy Adults and Dose Optimization Informed by Pharmacokinetics Modelling.Drug design, development and therapy · 2026Article
- Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study.BMC medicine · 2025Article
- Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DFThe Lancet regional health. Western Pacific · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ACC007 is a new-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with favorable pharmacokinetic and safety profiles. NNRTIs are typically administered in combination with two nucleoside reverse transcriptase inhibitors as first-line recommended regimens in several guidelines. Therefore, this open-label, randomized, single-period, parallel-cohort study aimed to assess the drug-drug interactions (DDIs) and safety profiles of ACC007 in combination with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) in healthy subjects. All 24 screened subjects were randomly assigned to group A or B. On days 1 to 17, 3TC at 300 mg and TDF at 300 mg were taken orally by group A, and ACC007 at 300 mg was coadministered on days 8 to 17. On days 1 to 17, 300 mg of ACC007 was taken orally by group B, and 300 mg 3TC and 300 mg TDF were coadministered on days 8 to 17. When we compared 3TC-TDF versus 3TC-TDF-ACC007 DDIs, the geometric mean ratios (GMRs, with 90% confidence intervals [CIs] in parentheses) of the maximum concentration at steady state (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.